Replimune has twice sought regulatory approval for its experimental melanoma drug, citing an unmet need for advanced ...

The biotech group has struggled as a whole in 2025, but analysts say the innovation that has always supported the biotech ...

Both Agenus AGEN and Iovance Biotherapeutics IOVA are small-cap companies focused on next-generation cancer immunotherapies ...

Biotech stocks are attracting investors as M&A activity, valuations and upcoming catalysts help drive sector momentum.

As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd.

The biotech sector has always held a special appeal for risk-tolerant investors. While these companies face high overhead in the form of towering R&D costs and long lead times for bringing new ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

When Wall Street’s growth-at-any-price trade cools, capital tends to rotate toward profitable, cash-generative healthcare ...

Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified ...

This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious ...

This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary ...